Dr Reddy’s Cheminor merger: A pharma wedding finalised - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • Jun 1, 2000 - Dr Reddy’s Cheminor merger: A pharma wedding finalised

Dr Reddy’s Cheminor merger: A pharma wedding finalised

Jun 1, 2000

Dr Reddy’s Laboratories (DRL) is to merge its sister concern Cheminor Drugs (Cheminor) with the merger ratio set at 9 shares of DRL for every 25 shares of Cheminor. The merger will make Dr. Reddy’s the third largest pharmaceutical player in India, with a post- integration turnover of above Rs. 8 billion in FY 2000. The management aims at a turnover of over Rs 10 bn in FY 2001 which it should it able to achieve if the growth in its main brands viz. Omez (anti–ulcer), Nise (anti–pain), Stamlo (cardivascular) and Ciprolet (anti–infective) in FY2000 are any indication. These brands contributed over 40% of the company’s turnover and will continue to be a major driver for the merged company’s topline.

Another driver of the topline would be the generics business in the regulated markets, which was being undertaken via Cheminor. (Cheminor recently entered the global generics markets with the export of Ranitidine-75Mg and Flouxetine to North America.)

The third driver of the integrated company’s turnover would be the revenues from any Novel Drug Discovery (NDDS). At present, DRL itself is working on three new molecules. One is an anti–cancer compound, another was a Cox II inhibitor (anti–pain) and third was a compound indicated for metabolic disorders. The company foresees licensing out two of these to MNCs for clinical trials in the near future. Besides, the company is also working on a new class of diabetes products called PPAR, expected to have considerable potential.

The main promoter of the group companies, Dr. Reddy’s Holdings (DRH), currently holds 25.40% in DRL and 35.34 % in Cheminor. The holding of DRH in the merged entity will be 27.59%. In their individual capacities, Dr. Anji Reddy and his immediate family members hold 1.76% in DRL and 13.42% in CDL. In the merged entity their combined holding will be 3.86%.

The merger ratio too seems to be slightly weighted in favour of the Cheminor considering the fact that its turnover was Rs 2154 m in FY 2000 i.e. around 36% of the DRL’s turnover. (DRL’s turnover inclusive of American Remedies’ numbers amounted to Rs 5870 m in FY2000.) Moreover growth in the domestic bulk actives market has actually been negative. However weightage seems to have been given to the fact that 67% of Cheminor’s turnover is accounted for by exports and the company has already filed six abbreviated new drug applications (ANDAs) in the US, four in the European Union apart from another six, which are in the pipeline.

Equitymaster requests your view! Post a comment on "Dr Reddy’s Cheminor merger: A pharma wedding finalised". Click here!


More Views on News

Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)

May 24, 2021

With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

Glenmark Life Sciences IPO Opens Tomorrow: Few Points to Know Before Applying (Views On News)

Jul 26, 2021

All you need to know about the IPO of Glenmark Life Sciences.

Why Did Pharma Stocks Surge? (Views On News)

Jul 17, 2021

A look into the factors contributing to the rally in pharma stocks.

Bajaj Healthcare Rallies 11% on DRDO Nod to Manufacture Oral Covid Drug (Views On News)

Jul 8, 2021

Bajaj Healthcare has more than doubled investors' wealth in the year 2021 so far. The counter has delivered over 240% return in the last one year.

More Views on News

Most Popular

RBI Opens a New Market for Investors (Fast Profits Daily)

Jul 16, 2021

You now have a new way to create wealth. Grab it with both hands.

These Are the Best Stocks to Own (Fast Profits Daily)

Jul 22, 2021

Find out what I think are the best kind on stocks to own in the market.

India's Vulture Moment Against China (Fast Profits Daily)

Jul 15, 2021

India has a great opportunity to grab market share from China. Profit from it.

Top 5 Stocks Mutual Funds Bought and Sold in June 2021 (Views On News)

Jul 15, 2021

A look at what India's top equity mutual funds bought and sold in June 2021.

Zomato: Worth a Bite? (Profit Hunter)

Jul 15, 2021

Zomato has been a consumer's delight. Can it be an investor's delight too?


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Jul 28, 2021 (Close)


  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks